1168 related articles for article (PubMed ID: 24838304)
1. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
Jang KM; Kim SH; Kim YK; Choi D
Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
[TBL] [Abstract][Full Text] [Related]
2. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
3. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC.
Kim YK; Lee WJ; Park MJ; Kim SH; Rhim H; Choi D
Radiology; 2012 Oct; 265(1):104-14. PubMed ID: 22891358
[TBL] [Abstract][Full Text] [Related]
4. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
Kim JE; Kim SH; Lee SJ; Rhim H
AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
[TBL] [Abstract][Full Text] [Related]
5. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.
Hyodo T; Murakami T; Imai Y; Okada M; Hori M; Kagawa Y; Kogita S; Kumano S; Kudo M; Mochizuki T
Radiology; 2013 Feb; 266(2):480-90. PubMed ID: 23362095
[TBL] [Abstract][Full Text] [Related]
6. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
Park MJ; Kim YK; Lee MH; Lee JH
Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
[TBL] [Abstract][Full Text] [Related]
8. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation.
Lee DH; Lee JM; Lee JY; Kim SH; Kim JH; Yoon JH; Kim YJ; Lee JH; Yu SJ; Han JK; Choi BI
J Hepatol; 2015 May; 62(5):1122-30. PubMed ID: 25529623
[TBL] [Abstract][Full Text] [Related]
9. Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization.
Hwang J; Kim YK; Jeong WK; Choi D; Rhim H; Lee WJ
Radiology; 2015 Jul; 276(1):137-46. PubMed ID: 25734551
[TBL] [Abstract][Full Text] [Related]
10. Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: observation in serial gadoxetic acid-enhanced MRI.
Yamamoto A; Ito K; Tamada T; Higaki A; Kanki A; Sato T; Tanimoto D
AJR Am J Roentgenol; 2013 Jun; 200(6):1254-60. PubMed ID: 23701061
[TBL] [Abstract][Full Text] [Related]
11. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
[TBL] [Abstract][Full Text] [Related]
13. Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging.
Briani C; Di Pietropaolo M; Marignani M; Carbonetti F; Begini P; David V; Iannicelli E
J Gastrointest Cancer; 2018 Sep; 49(3):302-310. PubMed ID: 28547117
[TBL] [Abstract][Full Text] [Related]
14. Hypovascular hypointense nodules on hepatobiliary phase without T2 hyperintensity on gadoxetic acid-enhanced MR images in patients with chronic liver disease: long-term outcomes and risk factors for hypervascular transformation.
Kim YS; Song JS; Lee HK; Han YM
Eur Radiol; 2016 Oct; 26(10):3728-36. PubMed ID: 26670318
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
16. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
[TBL] [Abstract][Full Text] [Related]
17. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
Kim SS; Kim SH; Song KD; Choi SY; Heo NH
J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
[TBL] [Abstract][Full Text] [Related]
18. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
[TBL] [Abstract][Full Text] [Related]
19. Non-hypervascular hypointense nodules detected by Gd-EOB-DTPA-enhanced MRI are a risk factor for recurrence of HCC after hepatectomy.
Toyoda H; Kumada T; Tada T; Niinomi T; Ito T; Sone Y; Kaneoka Y; Maeda A
J Hepatol; 2013 Jun; 58(6):1174-80. PubMed ID: 23376360
[TBL] [Abstract][Full Text] [Related]
20. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration.
Golfieri R; Grazioli L; Orlando E; Dormi A; Lucidi V; Corcioni B; Dettori E; Romanini L; Renzulli M
J Magn Reson Imaging; 2012 Sep; 36(3):648-57. PubMed ID: 22592930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
